The present invention relates to a novel human coagulation Factor VIIa variant having a substitution at position 286 in SEQ ID NO:1 and coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.